HK1178085A - Probiotic microorganisms as active agents for enhancing the radiance of the skin's complexion - Google Patents

Abstract

The invention relates to the use of at least one probiotic microorganism as an active agent for preventing and/or treating impaired radiance of the skin's complexion.

Description

Probiotic microorganisms as active agents for improving the radiance of skin complexion

Technical Field

The present invention relates to the use of probiotic micro-organisms for improving the radiance of skin tone, in particular for providing a shiny appearance to the skin tone of the facial skin.

More specifically, the present invention relates to the use of probiotic microorganisms, and in particular lactobacillus, as active agents that contribute to the treatment and/or prevention of impaired radiance of the skin complexion. The invention also relates to a method for making the skin tone of the skin more radiant or even shiny.

Background

Skin tone is an indication of the health status of skin, especially young skin.

Various external or internal factors (as noted below, among others) can cause skin imperfections and/or cause the skin tone to be chaotic or uneven. These skin color lesions are often of multifactorial origin and are responsible for the increasing frequency of consultation or skin surgery in beauty salons.

The radiance of the skin complexion may be affected by a number of extrinsic or intrinsic factors. Among the extrinsic factors, mention may be made of exposure to sunlight, exposure to temperature and humidity variations or exposure to contaminants. Among the intrinsic factors that influence the radiance of the skin complexion, mention may be made of stress, fatigue, hormonal changes, dehydration of the epidermis or impairment of the barrier function of the skin or even ageing. These extrinsic and intrinsic factors tend to chaotize, make the skin tone uneven, dull and pale, or even morbid, and promote or even exacerbate existing skin imperfections.

In its mild form, these lesions affect almost everyone, and they are most frequent in adolescent age. However, they may appear between the ages of 7 and 9 and may persist beyond 40, and especially may persist beyond 60. Thus, even after age 25, it is common to have skin imperfections (particularly on the face) and a chaotic, dull and/or uneven skin tone.

In its most severe form, these injuries can occasionally have the consequence of damaging the psychosocial aspects, which can lead to loneliness, or even frustration or loss of business for the affected individuals.

Therefore, there is a real need to be able to prevent, reduce or treat these skin complexion impairments.

WO 2006/104730 describes a food supplement comprising probiotic micro-organisms to improve the appearance of the skin and to prevent signs, such as a rough appearance or a pale appearance, and in particular age-related signs, on the skin.

However, it can be seen that none of the solutions proposed in the prior art satisfactorily prevent and/or treat the loss of radiance of the complexion of the skin.

Thus, there is a need for new active agents that help prevent and/or treat loss of radiance in skin complexion.

There is also a need for new active agents that can provide a bright skin tone to the skin.

There is also a need for new active agents for the prevention and/or treatment of skin defects.

Disclosure of Invention

The present invention aims to meet these needs.

According to a first subject, the present invention relates to the cosmetic use of at least one probiotic microorganism, and in particular of the genus lactobacillus, as an active agent contributing to the treatment and/or prevention of impaired radiance of the complexion of the skin.

Surprisingly, the inventors have found that the administration of a food supplement comprising probiotic micro-organisms, in particular the administration of micro-organisms of the genus lactobacillus, in particular lactobacillus paracasei and more particularly lactobacillus paracasei ST11, can substantially reduce skin defects, prevent and/or treat chaotic and/or uneven and/or dull skin complexion, or impart a significantly more radiant and shiny skin complexion to the skin.

According to one embodiment, the radiance damage of the skin's complexion considered in the present invention is independent of age, and in particular is not a sign of skin aging.

The use of probiotic micro-organisms according to the present invention advantageously may enhance the barrier function properties of the skin, thus promoting the integrity of the skin and maintaining the skin's complexion.

According to another advantage, the use according to the invention makes it possible to optimize the absorption in the intestinal mucosa of the nutrients provided by the food product and to promote the supply of nutrients necessary for the metabolism of the cells. Thus, the synthesis of various functional and structural components of the skin is promoted, so that it is possible to maintain the homeostasis of the skin and reduce the loss of radiance of the complexion, or even to enhance the radiance and brightness of the skin.

According to another preferred embodiment, the probiotic microorganism suitable for use in the present invention as an active agent contributing to the treatment and/or prevention of the impaired radiance of the complexion of the skin may advantageously be a lactobacillus, in particular as defined below.

According to one embodiment, the subject of the present invention is also a cosmetic process for preventing and/or treating impaired radiance of the complexion of the skin, comprising the administration of at least one probiotic microorganism, in particular of the lactobacillus genus, in particular as defined below.

According to the invention, the term "skin" is intended to mean all the epidermis of an individual, in particular a human, and more particularly the skin of the neck, neck and face, in particular the skin of the face.

According to one embodiment, the use according to the invention advantageously makes it possible to prevent and/or treat loss of radiance of the complexion of the skin.

As noted above, the radiance of the skin's complexion may be adversely affected by either intrinsic or extrinsic factors as described above.

The skin color reflects the health of the skin.

A shiny, shiny or even glowing skin tone is an indication of well-conditioned skin, whose properties and barrier function are perfectly adjusted.

Thus, the use of probiotic microorganisms according to the present invention advantageously makes it possible to modulate the homeostasis of the skin in order to impart a shiny, shinier or even more radiant complexion to the skin.

According to one embodiment, the use according to the invention advantageously makes it possible to prevent and/or treat chaotic, dull and/or uneven skin complexion.

According to another embodiment, the use according to the invention advantageously makes it possible to prevent and/or treat skin defects, chosen in particular from spots (spots), skin diseases (dartres), skin discolouration, age marks, blackheads and/or chloasma.

According to another embodiment, the use according to the invention advantageously makes it possible to prevent and/or treat skin defects selected from the group consisting of spots, skin diseases, age spots, blackheads and/or chloasma.

According to another embodiment, the use according to the invention advantageously makes it possible to prevent and/or treat pale, yellowish or even morbid skin tones.

According to another embodiment, the skin color damage contemplated in the present invention is unrelated to oily skin, greasy prone skin, or acne skin.

According to another embodiment, the skin considered in the present invention is not aged skin or oily skin or skin prone to greasiness.

According to one embodiment, the probiotic microorganisms suitable for use in the present invention may be administered orally, topically or parenterally, in particular orally.

The use of the microorganism according to the invention must be carried out in an effective amount, i.e. an amount that causes the probiotic microorganism to exhibit its active properties on the lustrous lesions of the skin complexion to be prevented and/or treated.

For the purposes of the present invention, the term "prevention" means at least partially reducing the risk of the manifestation of the particular condition, i.e. the impairment of the skin complexion in the present invention. Partial reduction means that there is still a risk, but to a lesser extent than before the present invention was implemented.

Microorganisms

For the purposes of the present invention, the term "Probiotic microorganism" means a Live microorganism which, when consumed in sufficient amounts, has a positive effect on the Health of its host ("Joint FAO/WHO Expert consensus evaluation of Health and Nutritional Properties of biological in Food containing powder Milk with Live Lactic Acid Bacteria, 2001, 6 days 10), and which can improve the microbial balance of the intestinal tract in particular.

According to one embodiment, the probiotic microorganisms according to the invention may be used in isolated form or in purified form, i.e. without being mixed with one or more compounds in their source medium which are easily associated therewith.

According to another embodiment, the probiotic micro-organisms according to the invention may be used in a live, semi-live, inactivated or dead form.

According to an advantageous embodiment of the invention, the probiotic microorganisms may advantageously be used in inactivated or dead form.

The probiotic micro-organisms for topical administration may advantageously be used in inactivated or dead form.

The probiotic micro-organisms for oral administration may advantageously be used in a live form.

For the purposes of the present invention, an "inactivated" microorganism is a microorganism which is no longer capable of forming colonies, either temporarily or certainly, in the culture medium. For the purposes of the present invention, a "dead" microorganism is a microorganism which is no longer capable of forming colonies with certainty in the culture medium. Dead or inactivated microorganisms may have intact or disrupted cell membranes. Thus, the term "inactivated" also refers to microbial extracts and lysates as described in detail below. Dead or inactivated microorganisms may be produced by any method known to those skilled in the art.

According to an advantageous embodiment, the probiotic microorganisms used according to the invention are at least partially inactivated or dead.

The expression "at least partially inactivated or dead" probiotic micro-organisms means that the preparation of probiotic micro-organisms according to the invention comprises: at least 80%, in particular at least 85%, more in particular at least 90%, or even at least 95%, or at least 99% of the inactivated or dead probiotic microorganisms relative to the total amount of non-inactivated live probiotic microorganisms contained in the initial formulation prior to being subjected to the method of inactivating or killing the microorganisms.

The degree of inactivation or degree of death obtained depends on the application conditions of the method used, which are adjusted by the person skilled in the art according to the degree of inactivation or degree of death to be obtained.

According to one embodiment, the invention comprises the use of a preparation comprising 100% inactivated or killed probiotic micro-organisms.

The inactivated probiotic microorganisms suitable for use in the present invention may be prepared by irradiation, heat-inactivation or lyophilization of microbial preparations. These methods are known to those skilled in the art.

More specifically, inactivating probiotic microorganisms by radiation methods may include the use of gamma rays, x-rays, exposure to UV or heat conditions, or reduced pressure. The type, intensity, dosage and exposure time of the treatment are adjusted by the person skilled in the art according to the amount and nature of the probiotic microorganism to be inactivated.

According to a variant of a preferred embodiment, the probiotic microorganisms suitable for use in the present invention are used in an inactivated form obtained by irradiation methods, and in particular gamma irradiation.

Inactivation by lyophilization may be accomplished by any method known in the art. Advantageously, the probiotic microorganisms inactivated by lyophilization may be re-cultured.

Heat inactivation may be performed by culturing the probiotic microorganism of the present invention at 170 ℃ for a prolonged period of time (e.g. at least two hours). Heat inactivation may also be performed by autoclaving by subjecting the probiotic microorganisms of the invention to a temperature of 121 ℃ and an atmospheric pressure of 2 bar for a period of at least 20 minutes.

Alternatively, the heat inactivation may be performed by subjecting the probiotic micro-organisms to a freezing temperature for a prolonged period of time.

The probiotic microorganism according to the invention may be used in intact form, i.e. essentially in its native form; or in the form of an extract or lysate comprising a disintegrated suspension of a fraction (fraction) and/or metabolites of the microorganism according to the invention.

For the purposes of the present invention, the term "metabolite" denotes any substance originating from the metabolism of microorganisms and being secreted in particular by the microorganisms considered according to the invention and also being endowed with the efficacy of treating and/or preventing the loss of radiance of the complexion of the skin.

For the purposes of the present invention, by analogy with said intact microorganisms, the term "fraction" more particularly denotes the fragments of said microorganisms which are endowed with the efficacy of treating and/or preventing loss of radiance of the complexion of the skin.

Extracts or lysates suitable for use in the present invention can be prepared from probiotic microorganisms at the end of the growth phase.

According to a preferred embodiment, the probiotic microorganisms suitable for use in the present invention may be used in the form of a lysate.

For the purposes of the present invention, "lysate" generally denotes a material that: material obtained after destruction or lysis of biological cells by means of a phenomenon known as cytolysis, thus causing the release of intracellular biological components naturally contained in the cells of the microorganism in question.

For the purposes of the present invention, the term "lysate" is used without preference to denote the complete lysate or only a part thereof obtained by lysis of the microorganism in question.

Thus, the lysate used is formed wholly or partly from intracellular biological components and components of the cell wall and cell membrane.

Advantageously, the lysate used in the present invention may be the total lysate obtained by means of lysis of the microorganism in question.

This cell lysis can be accomplished by various techniques, such as osmotic shock, thermal shock, ultrasonication or optionally under mechanical stress of the centrifugal separation type.

More specifically, the cell lysate can be obtained according to the technique described in patent US4,464,362, and in particular according to the following rules.

In particular, the lysate of the present invention may be broken by means of sonication of the culture medium comprising the probiotic microorganisms in suspension in order to release therefrom the cytoplasmic fraction, cell wall fragments and products obtained from metabolism. All components in their naturally distributed form are then stabilized in a weakly acidic aqueous solution.

The microorganism, extract or lysate may be used in various forms, such as a solution, culture supernatant, powder (optionally lyophilized) or concentrate.

According to one embodiment, the probiotic micro-organisms suitable for use in the present invention may be selected from the group consisting of lactobacillus, bifidobacterium, coccus, yeast, sporotrichiomycetes and mixtures thereof.

According to one embodiment, the microorganisms suitable for use in the present invention are preferably selected from:

-ascomycetes (ascomycetes): especially yeasts (Saccharomyces), especially Saccharomyces cerevisiae (s.cerevisiae) or Saccharomyces boulardii (s.boulardii); yarrowia (Yarrowia), in particular Yarrowia lipolytica (y. lipolytica); kluyveromyces (Kluyveromyces); torulaspora (Torulaspora), Schizosaccharomyces pombe (Schizosaccharomyces pombe); debaryomyces (Debaromyces); candida genus (Candida); pichia (Pichia); aspergillus (Aspergillus), especially kluyveromyces lactis (k.lactis) and Penicillium (Penicillium);

spore bacteria (sporogenic bacteria): in particular Bacillus (Bacillus sp.), in particular Bacillus cereus (b.subtilis) or Bacillus subtilis (b.coagulans), Bacillus coagulans (b.coemulans), Bacillus licheniformis (b.licheniformis); escherichia (Escherichia sp.), in particular the Escherichia coli strain nissle (e.coli strain nissle); propionibacterium (propionibacterium sp.), in particular propionibacterium freudenreichii (p. freudenreichii); bacteroides (Bacteroides sp.); clostridium (Fusobacterium sp.); and Weissella (Weissella sp.);

-Cocci (Cocci): particularly the genus Melissococcus (Melissococcus sp.); staphylococcus (Staphylococcus sp.), especially Staphylococcus carnosus (s.carnosus) or Staphylococcus xylosus (s.xylosus); peptostrococcus sp.); pediococcus sp, especially Pediococcus acidilactici (p. acidilactici); micrococcus (Micrococcus sp.); leuconostoc sp, especially Leuconostoc mesenteroides (L.mesenteroides subsspdarrangement); aerococcus (Aerococcus sp.); oenococcus sp.); enterococcus (Enterococcus sp.), especially Enterococcus faecalis (e.faecalis) or Enterococcus faecium (e.faecalis); lactococcus sp, in particular Lactococcus lactis subsp lactis (l.lactis subsp lactis) or Lactococcus cremoris (l.cremoris); lactobacillus (Sporolactobacillus sp.), especially lactobacillus inulinus (s. inulinus); and Streptococcus (Streptococcus sp.), especially Streptococcus salivarius subsp.thermophilus (S.salivarius subsp.Thermophilus) or Streptococcus thermophilus (S.thermophilus),

lactobacillus species (Lactobacillus species): in particular lactobacillus paracasei (l.paracasei), lactobacillus acidophilus (l.acidophilus), lactobacillus amylovorus (l.amylovorus), lactobacillus casei (l.casei), lactobacillus rhamnosus (l.rhamnosus), lactobacillus brevis (l.breves), lactobacillus crispatus (l.crispatus), lactobacillus delbrueckii subsp.lactis (l.delbrueckii subsp.lactis), lactobacillus bulgaricus (l.bulbgaricus), lactobacillus fermentum (l.fermentum), lactobacillus helveticus (l.helveticus), lactobacillus helveticus (l.gallinarum), lactobacillus griseus (l.gasseri), lactobacillus johnsonii (l.johnsonii), lactobacillus plantarum (l.plantarum), lactobacillus reuteri (l.reuteri), lactobacillus salivarius (l.salivarius), lactobacillus casei (l.curus), lactobacillus casei.L.curus), lactobacillus casei (l.branheimeria), lactobacillus delbrueckii subsp.l.

Bifidobacteria (bifidobacteria) or bifidobacteria species (bifidobacteria species): bifidobacterium adolescentis (B.adolescentis), Bifidobacterium animalis (B.animalis), Bifidobacterium bifidum (B.bifidum), Bifidobacterium breve (B.breve), Bifidobacterium lactis (B.lactis), Bifidobacterium longum (B.longum), Bifidobacterium infantis (B.infantis), Bifidobacterium pseudocatenulatum (B.pseudocatenulatum),

-and mixtures thereof.

More specifically, it may be a probiotic microorganism selected from the group consisting of lactobacillus, enterococcus, lactococcus, bacillus, streptococcus, pediococcus, leuconostoc or bifidobacterium (and in particular from the group consisting of lactobacillus, bifidobacterium) and mixtures thereof.

As examples of probiotic microorganisms suitable for use in the present invention, mention may be made of Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium pseudocatenulatum, Lactobacillus acidophilus NCFB 1748, Lactobacillus paracasei, Lactobacillus amylovorus, Lactobacillus casei (Shirota), Lactobacillus rhamnosus GG strain (L.rhamnosus strain GG), Lactobacillus brevis, Lactobacillus crispus, Lactobacillus bulgaricus, Lactobacillus delbrueckii subsp.lactis, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus griseus, Lactobacillus johnsonii CNCM I-1225 (L.johnsonii CNCM I-1225), Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus digestus, Lactobacillus curvatus, Lactobacillus casei, Lactobacillus sake, Lactobacillus sakei, Lactobacillus sake, Lactobacillus sakei, Lactobacillus sake Lactobacillus, Lactobacillus casei, Lactobacillus brevis, Lactobacillus casei, Lactobacillus kei, Lactobacillus casei, Lactobacillus del, Enterococcus faecium, Lactococcus lactis subsp lactis, Lactococcus lactis cremoris (l.lactis subsp cremoris), Leuconostoc mesenteroides subsp.dextrans (Leuconostoc mesenteroides subsp.dextranum), pediococcus acidilactici, lactobacillus inulinus, streptococcus salivarius thermophilus subsp.thermophilus, staphylococcus carnosus, staphylococcus xylosus, saccharomyces cerevisiae, saccharomyces boulardii (s.boulardii), Bacillus cereus (Bacillus cereus toyo), Bacillus subtilis, Bacillus coagulans, Bacillus licheniformis, escherichia coli strain nissle, propionibacterium freudenreichii, and mixtures thereof.

As more specific examples of probiotic microorganisms suitable for use in the present invention, mention may advantageously be made of Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus digestus, Lactobacillus casei subsp.

More specifically, as probiotic microorganisms suitable for use in the present invention, there may be mentioned Lactobacillus johnsonii or Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus digestive, Lactobacillus curvatus, Lactobacillus delbrueckii subspecies lactis, Lactobacillus gasseri, Lactobacillus sake, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum and mixtures thereof.

Species particularly suitable for use in the present invention are the budapest treaty under 30/06/92, 12/01/99, 15/04/99 and 15/04/99, lactobacillus johnsonii, lactobacillus paracasei, bifidobacterium adolescentis, bifidobacterium longum, and bifidobacterium lactis (Bb 12) (ATCC 27536) or bifidobacterium longum (Bb 536) deposited at the pasteur institute (28rue du Docteur Roux, F-75024Paris cedex 15) under the names CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, respectively. A strain of Bifidobacterium lactis (ATCC 27536) can be obtained from Hansen (Chr. Hansen A/S, 10-12BoegeAlle, P.O.Box 407, DK-2970, Haosholm, Denmark).

Advantageously, the microorganism suitable for use in the present invention may be a lactic acid probiotic microorganism, which produces lactic acid by fermenting sugars.

According to a preferred embodiment, the probiotic microorganisms suitable for use in the present invention, for example topically or orally, and in particular orally, may in particular be microorganisms of the genus lactobacillus.

Preferably, the microorganism of the genus lactobacillus suitable for use in the present invention may be selected from the group consisting of lactobacillus johnsonii, lactobacillus acidophilus, lactobacillus reuteri, lactobacillus paracasei, lactobacillus casei and mixtures thereof.

According to a preferred embodiment, the microorganisms suitable for use in the present invention may be selected from the group consisting of lactobacillus paracasei, lactobacillus johnsonii, lactobacillus acidophilus and mixtures thereof.

According to a preferred embodiment, the microorganism suitable for use in the present invention may be lactobacillus paracasei.

According to another preferred embodiment, the microorganism suitable for use in the present invention may be in particular the strain Lactobacillus paracasei ST11 deposited under the name CNCM I-2116 according to the Budapest treaty signed at the institute for Pasteur (28rue du Docteur Roux, F-75024Paris cedex 15) on 30.6.1992.

According to one embodiment, the probiotic microorganisms suitable for use in the present invention are administered orally, parenterally or topically.

The term "parenteral" route means a route different from the oral route and the topical route of administration. The parenteral route suitable for use in the present invention may be, for example, the nasal route

According to a preferred embodiment, the probiotic micro-organisms suitable for use in the present invention are topically applied.

The topical route advantageously allows a local effect to be obtained for the desired effect.

According to another preferred embodiment, the probiotic microorganisms suitable for use in the present invention are administered orally or parenterally, in particular orally.

The oral route or the parenteral route advantageously allows to obtain a full effect with respect to the desired effect.

The microorganism according to the invention may be formulated in the composition in a proportion of at least 0.0001% (expressed in dry weight), in particular in a proportion of from 0.0001% to 30%, in particular in a proportion of from 0.001% to 20% and more particularly in a proportion of from 0.01% to 15%, in particular in a proportion of from 0.1% to 10% and in particular in a proportion of from 1% to 5%, by weight of the microorganism relative to the total weight of the composition containing the microorganism.

In general, the composition according to the invention intended for oral administration may comprise from 10 viable microorganisms per gram of viable microorganisms for which the composition may be intended³cfu/g to 10¹⁵cfu/g, in particular from 10⁵cfu/g to 10¹⁵cfu/g and especially from 10⁷cfu/g to 10¹²cfu/g, either for inactivated or dead microorganisms or for microbial fractions or for metabolites produced, including calculated equivalent doses.

In particular, in compositions for oral administration, the concentration of the corresponding microorganism and/or fraction and/or metabolite may be adjusted so as to correspond to an expression from 5 × 10 in terms of microbial equivalents (equivalents)⁵cfu/day to 10¹³cfu/day and especially from 10⁸cfu/day to 10¹¹Dose cfu/day.

The composition for topical application according to the invention may generally comprise said microorganisms in the following proportions by weight per gram of composition, relative to the total weight of the composition containing said microorganisms: from 0.0001% to 30%, in particular from 0.001% to 20%, more particularly from 0.01% to 15%, in particular from 0.1% to 10% and in particular from 1% to 5%.

In the particular case of topical administration, it may be advantageous to use the microorganisms in inactivated or even dead form, in particular in the form of extracts or lysates.

The microorganism may also be included in the composition in the form of a fraction of a cellular component or in the form of a metabolite, in particular a lysate. The microorganisms, metabolites or fractions may also be introduced in the form of a lyophilized powder, culture supernatant and/or, where appropriate, in the form of a concentrate.

When the composition includes a metabolite, the metabolite is present in the composition in an amount corresponding substantially to a metabolite content of 10 per gram of the composition³cfu to 10¹⁵cfu, especially 10⁵cfu to 10¹⁵cfu and more particularly from 10⁷cfu to 10¹²content of viable micro-organisms produced by cfu.

The expression of the amount of a metabolite or fraction of a microorganism or dead microorganism with "cfu" is intended to mean the amount of the microorganism used to prepare the metabolite or fraction of the microorganism.

Composition comprising a metal oxide and a metal oxide

The probiotic microorganisms suitable for use in the present invention are advantageously formulated in a composition which may be in any form of formulation which is generally useful for the selected mode of administration.

The composition according to the invention comprises a physiologically or pharmaceutically acceptable medium.

The compositions according to the invention can be administered orally, parenterally, in particular subcutaneously or intradermally, or topically.

Preferably, the compositions of the present invention may be administered topically.

According to one embodiment, the topical composition according to the invention may advantageously be formulated in any formulation suitable for the care of the skin and mucous membranes and may be in the form of an ointment, cream, emulsion, hair cream, powder, impregnated tampon, solution, gel, spray, lotion or suspension. They may also be in the form of microspheres or nanospheres or lipid or polymer vesicles or polymer patches and hydrogels allowing controlled release. These topical compositions may be in anhydrous form or in aqueous form, depending on the medical skin care instructions.

Compositions for topical administration may be: aqueous, hydroalcoholic or oily solutions, solutions or dispersions of the lotion or cream type, emulsions of liquid or semi-liquid consistency of the emulsion type obtained by dispersing an oil-in-water phase (O/W) or a water-in-oil phase (W/O), suspensions or emulsions of soft, semi-solid or solid consistency of the cream type or of the aqueous type or of the anhydrous gel type, multiple emulsions (W/O/W or O/W/O), microemulsions, nanoemulsions, preparations of microcapsules, preparations of microparticles, vesicular dispersions of the ionic or nonionic type, or waxy/aqueous dispersions.

According to a preferred embodiment, the topical composition may be in the form of a solution, cream, gel, emulsion, mousse or aerosol composition containing a propellant.

According to a preferred embodiment, the topical composition may also be in the form of a transdermal system for the active or passive transdermal release of the active agent, for example of the patch or gel patch (hydrogel) type.

These compositions are prepared according to the usual methods.

The composition according to the invention may constitute a composition for treating or caring for the skin or scalp, or an anti-sun or artificial tanning (anti-sun) composition or alternatively a skin cleansing or makeup-removing preparation, a deodorant preparation or a scented compound.

Such compositions may then be uncolored or lightly colored, and may optionally contain other cosmetic or dermatological active agents, as particularly noted below. It can then be used as a care base for the skin or the lips, for example in the form of a lipstick protecting the lips from cold and/or sunlight and/or wind, or as a day care cream or night care cream for the facial skin and/or body skin.

It may also be in the form of medicated or non-medicated, colored or non-colored shampoos or conditioners.

The composition according to the invention may also constitute a pigmented cosmetic composition and in particular a cosmetic composition for the skin and/or mucous membranes. In particular, such a composition may be a foundation, blush, face powder, eye shadow, concealer compound in the form of a stick, lipstick or lip gloss optionally having care or therapeutic properties. Preferably, it may be a pigmented (beige or green) cosmetic composition for correcting skin tone.

The compositions for topical administration may constitute, in particular, cleansing, protective treatment or care creams, skin care lotions, gels or mousses, cleansing or antiseptic lotions, bath compositions or deodorant compositions.

The composition according to the invention may also consist of a solid preparation constituting a cleansing soap or a cleansing bar.

When the composition of the invention is an emulsion, the proportion of the fatty phase may be from 5% to 80%, preferably from 10% to 50%, by weight of the fatty phase relative to the total weight of the composition. The oils, emulsifiers and co-emulsifiers used in the compositions in emulsion form are chosen from those conventionally used in cosmetics and/or dermatology. The emulsifiers and co-emulsifiers may be present in the composition in a proportion of from 0.3% to 30%, preferably from 0.5% to 20%, by weight thereof relative to the total weight of the composition.

When the composition of the invention is an oily gel or an oily solution, the fatty phase may represent more than 90% of the total weight of the composition.

Formulations intended for topical administration may also contain, in a known manner, adjuvants customarily employed in the cosmetic, pharmaceutical and/or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, masking agents, odor absorbers and colorants. The amounts of these various adjuvants are those conventionally used in the field under consideration, for example from 0.01% to 20% of the total weight of the composition. Depending on their nature, these adjuvants may be introduced into the fatty phase and/or the aqueous phase.

As fatty substances that can be used in the present invention, mention may be made of: mineral oils such as hydrogenated polyisobutene and liquid petrolatum; vegetable oils, such as liquid fractions of shea butter, sunflower oil and almond oil; animal oils, such as squalane; synthetic oils, especially duck tailed oil (purcellin oil), isopropyl myristate and isooctyl palmitate, unsaturated fatty acids; and fluoro oils such as perfluoropolyethers. Fatty alcohols, fatty acids (e.g. stearic acid) and waxes such as paraffin, carnauba and beeswax, among others, may also be used. Silicone compounds such as silicone oils (e.g., cyclomethicone and dimethicone) and silicone waxes, silicone resins, and silicone gums may also be used.

As emulsifiers which can be used in the present invention, examples which may be mentioned include glyceryl stearate, polysorbate 60, the name Sinnaowax by Henkel, GermanyCetearyl alcohol/cetostearyl alcohol oxyethylenated with 33mol of ethylene oxide sold under the name GattefossThe PEG-6/PEG-32/ethylene glycol stearate mixture sold as 63, PPG-3 myristyl ether, a silicone emulsifier such as cetyl dimethicone, and sorbitol monostearate or sorbitan tristearate, PEG-40 stearate and oxyethylenated (20 OE) sorbitol monostearate.

As the solvent which can be used in the present invention, there can be mentioned lower alcohols, particularly ethanol, isopropanol and propylene glycol.

The composition of the invention may also advantageously contain spring and/or mineral water, in particular water chosen from Vittel water, Vichy basin and Roche Posay water.

Hydrophilic gelling agents which may be mentioned include: carboxylic acid polymers, such as carbomer; acrylic copolymers, e.g. acrylate/alkylacrylate copolymers, polyacrylamides and especially Sepigel from SEPPICPolyacrylamide sold under the trade mark C_13-14Is different fromA mixture of paraffins and Laureth-7 (Laureth-7); polysaccharides, for example cellulose-based derivatives, such as hydroxyalkyl celluloses and in particular hydroxypropyl cellulose and hydroxyethyl cellulose; natural gums such as guar gum, locust bean gum, and xanthan gum; and clay.

Lipophilic gelling agents which may be mentioned include: modified clays, such as bentonite; metal salts of fatty acids, such as aluminum stearate; hydrophobic silica; or alternatively ethyl cellulose and polyethylene.

In the case of the compositions according to the invention for oral administration, it is preferable to use an absorbable carrier.

The absorbable carrier may be a variety of natural substances depending on the type of composition under consideration.

Thus, tablets, gel capsules or lozenges, suspensions, oral supplements in dry form and oral supplements in liquid form are particularly suitable for use as food carriers.

Milk, yoghurt, cheese, fermented milks, milk-based fermented products, ice-creams, cereal-based products or fermented cereal-based products, milk-based powders, baby foods, confectionery-type food products, chocolate, cereals or animal feeds, especially for pets, are also suitable as food carriers.

The term "oral composition" denotes, for example, a nutritional, nutraceutical, cosmeceutical or pharmaceutical composition comprising at least one probiotic microorganism according to the invention.

The formulation of the oral compositions according to the invention can be achieved by means of any of the usual methods known to the person skilled in the art for the preparation of drinkable solutions, sugar-coated tablets, gel capsules, gels, emulsions, tablets to be swallowed or chewed, glutinous rice capsules (wafer capsules), in particular soft or hard glutinous rice capsules, granules to be dissolved, syrups, solid or liquid foods and hydrogels allowing controlled release.

In particular, the probiotic micro-organisms according to the invention may be added to any form of food supplement or fortified nutritional food, such as food bars, or compacted or loose powders. The powder may be diluted with water, soda, dairy products or soy derivatives, or may be added to food bars.

According to one embodiment, the composition according to the invention for oral administration may be formulated in the form of sugar-coated tablets, gel capsules, gels, emulsions, tablets, glutinous rice capsules, hydrogels, food bars, compressed or loose powders, liquid suspensions or solutions, candies, fermented cheeses, chewing gums, toothpastes or spray solutions.

The oral composition may be in an anhydrous form or an aqueous form according to medical skin care instructions.

Furthermore, the probiotic microorganisms of the invention may be formulated from excipients and the usual ingredients of such oral compositions or food supplements, namely in particular fatty and/or aqueous ingredients, humectants, thickeners, preservatives, texturizers, flavour enhancers and/or coating agents, antioxidants and preservatives.

Formulation agents and excipients for oral compositions and especially for food supplements are known in the art and will not be the subject of the detailed description herein.

According to a preferred indication of the use of the probiotic micro-organisms of the invention, the composition of the invention will be a cosmetic, dermatological or pharmaceutical composition.

In particular, the composition according to the invention may be a food composition for human consumption. It may in particular be one of the following cases: nutritional foods, beverages, mineral waters, soups, dietary supplements and substitute foods, nutritional bars, confectionery, fermented or unfermented milk-based products, yoghurt-based products, milk-based powders, enteral nutritional products, infant and/or toddler compositions, fermented or unfermented cereal-based products, ice cream, chocolate, coffee or "culinary" products such as mayonnaise, ketchup or salad dressings.

The compositions according to the invention may also be used in animals, especially pets such as cats and dogs, and may be formulated in the form of a feed or food supplement for animals.

According to a preferred embodiment, the probiotic microorganisms suitable for use in the present invention may be administered parenterally, in particular subcutaneously or intradermally.

In such use, the probiotic microorganisms suitable for use in the present invention may be in the form of an aqueous or non-aqueous sterile isotonic solution, dispersion, suspension or emulsion, prepared by: where appropriate, sterile powders (e.g., lyophilized powders) are employed prior to administration, and are subsequently reconstituted at the time of use in the form of an injectable sterile solution or dispersion.

The term "sterile" defines a formulation capable of ensuring the required harmlessness of intraepidermal and/or intradermal and/or subcutaneous administration.

Compositions suitable for use in the present invention may include any excipient commonly used in the field of injectable sterile solutions.

Parenteral administration of the compositions of the invention may be carried out by any injection technique suitable for intradermal injection and/or subcutaneous injection. Thus, such administration may be performed through needles that are typically used to perform intradermal injections and/or subcutaneous injections suitable for cosmetic procedures.

Additional active agents

The probiotic microorganisms according to the invention may advantageously be used in combination with further active agents, in particular cosmetic or pharmaceutical active agents.

Advantageously, such further cosmetic or pharmaceutical active agents may be used to exert a cosmetic, care or hygiene effect on the skin, hair, eyelashes, body hair and/or scalp and preferably the skin.

The additional active agents are selected by the person skilled in the art such that these do not impair the action of the probiotic microorganisms of the invention.

In particular, additional active agents suitable for use in the present invention may be selected from active agents used to strengthen the skin barrier.

According to another embodiment, an active agent for the prevention and/or treatment of skin diseases can be combined with the microorganism according to the invention.

As further active agents that may be used, mention may be made of:

vitamins, such as vitamin A, vitamin B5, vitamin B6, vitamin B8, vitamin C, vitamin D, vitamin E or vitamin PP (vitamin B3 or niacin),

antioxidants, for example: curcuminoids; carotenoids, especially selected from the group consisting of beta-carotene, lycopene, astaxanthin, zeaxanthin and lutein; polyphenolic compounds, such as flavonoids of catechins; proanthocyanidins, anthocyanidins, and PCO (procyanidin oligomers); ubiquinone; coffee extract containing polyphenols and/or diterpenes; chicory extract; a ginkgo biloba extract; proanthocyanidin-rich grape extract; a Capsicum annuum extract; an extract of a soybean plant having a high content of soybean,

minerals, such as zinc, calcium, magnesium, copper, iron, iodine, manganese, selenium or chromium (III),

-a saccharide,

amino acids, in particular sulfur-containing amino acids, such as glutathione precursors, taurine,

-tri-and hexa-membered polyunsaturated fatty acids,

prebiotics, in particular selected from oligosaccharides made from chewing gums of the type such as glucose, galactose, xylose, maltose, sucrose, lactose, starch, xylan, hemicellulose, inulin, gum arabic or mixtures thereof. More specifically, the oligosaccharide comprises at least one fructooligosaccharide. More specifically, the prebiotic may comprise a mixture of fructooligosaccharides and inulin,

-phytosterols, such as resveratrol,

-hesperetin, and

mixtures thereof.

According to one embodiment, the protein or protein hydrolysate, amino acids, polyols (especially C)₂To C₁₀Such as glycerol, sorbitol, butylene glycol and polyethylene glycol), urea, allantoin, saccharides and sugar derivatives, water-soluble vitamins, starch, and bacterial or plant extracts (e.g. aloe extracts) can be used more particularly as additional hydrophilic active agents in the form of topical crude drugs.

According to another embodiment, retinol (vitamin a) and its derivatives, tocopherol (vitamin E) and its derivatives, ceramides, volatile oils and unsaponifiable materials (tocotrienols, sesamin, gamma-oryzanol, phytosterols, squalene, waxes and pinenes) may be more particularly used as additional lipophilic active agent in the form of topical crude drugs.

According to another embodiment, the topical crude drug forms suitable for use in the present invention may comprise at least one anti-aging active agent as an additional active agent.

Such anti-aging active agents may be selected in particular from moisturizers, desquamating agents, agents for improving barrier function, depigmenting agents, antioxidants, skin-relaxing agents (dermo-deconstruction agents), anti-glycation agents, agents for stimulating the synthesis of dermal and/or epidermal macromolecules and/or for preventing the degradation of these macromolecules, agents for stimulating fibroblast proliferation or keratinocyte proliferation and/or keratinocyte differentiation, agents for promoting the maturation of the keratinocyte envelope, NO-synthase inhibitors, Peripheral Benzodiazepine Receptor (PBR) antagonists, agents for stimulating the energy metabolism of cells, tensioning agents and agents for promoting the cutaneous microvascular circulation.

According to another embodiment, depigmenting or skin lightening agents can advantageously be used as further active agents in the form of topical crude drugs.

Such depigmenting or whitening agents may be chosen in particular from at least one extract of mint, and more particularly from: peppery mints; vitamin C and derivatives of vitamin C, such as vitamin CG or vitamin CP and 3-O-ethyl vitamin C; polyphenols, such as ellagic acid; ferulic acid; lucinol and derivatives thereof; kojic acid; alpha-arbutin and beta-arbutin and their derivatives; hydroquinone; an aminophenol derivative; an iminophenol derivative; l-2-oxothiazoline-4-carboxylic acid or propylcysteine and their salts and esters; resorcinol and resorcinol derivatives; tranexamic acid and derivatives of tranexamic acid; gentisic acid, homogentisic acid and methyl gentisate; a diacid; calcium D-pantetheine sulfonate; lipoic acid; vitamin B3; linoleic acid and derivatives of linoleic acid; ceramides and ceramides homologs; and plant extracts, in particular those chosen from licorice, mulberry, scutellaria, bacopa monnieri, chamomile, bearberry, aloe (vera), ferox (ferox) or bardas (bardensis)), kiwi (kiwifruit chinese) juice, or extract of the root of peony, this list being not limitative.

According to another embodiment, the topical crude drug form suitable for use in the present invention may comprise at least one exfoliating agent as an additional active agent.

Such release agents may be chosen in particular from: water of alpha-and beta-hydroxy acids, glycolic acid, citric acid, lactic acid, tartaric acid, malic acid, phenylglycolic acid, salicylic acid and especially-n-octanoylsalicylic acidA salicylic acid derivative; pyruvic acid, gluconic acid, glucuronic acid, oxalic acid, malonic acid, succinic acid, acetic acid, gentisic acid, phenylacrylic acid, or azelaic acid; phenol, resorcinol; urea and urea derivatives; oligofucose (oligofucoses); jasmonic acid and derivatives of jasmonic acid; trichloroacetic acid; retinoids, such as retinol or retinoic acid; adapalene (adapalene); an extract of Sophora japonica (Saphora japonica); resveratrol; enzymes involved in the exfoliation or degradation of keratinocyte desmosomes (corneodesmosomes), such as glycosidases, cuticle chymotrypsin (SCCE) or other proteases; mineral salt chelating agents, such as EDTA; N-acyl-N, N' -ethylenediaminetriacetic acid; sulfamic acid compounds and especially (N-2-hydroxyethylpiperazine-N-2-ethyl) sulfonic acid (HEPES); derivatives of 2-oxothiazoline-4-carboxylic acid (propylcysteine); derivatives of alpha-amino acids (such as glycine); honey; sugar derivatives such as O-octanoyl-6-D-maltose, O-linoleoyl-6-D-glucose, N-acetamido-glucosamine; extracts of laminaria plants such as giant kelp broadleaf kelp and kelp, glycerol trilactate, and derivatives containing silicon salicylate; and extracts of Opuntia ficus-indica flowers, e.g. from Rubia cordifolia (Silab)

Any commonly used and/or approved ingredient may also be considered for the additional active agent in the form of an oral crude drug.

By way of illustration, mention may be made of vitamins, minerals, essential fats, trace elements, polyphenols, flavonoids, phytoestrogens, antioxidants such as lipoic acid and coenzyme Q10, carotenoids, prebiotics, proteins and amino acids, mono-and polysaccharides, amino sugars, phytosterols and triterpene alcohols of plant origin.

This relates in particular to vitamin a, vitamin C, vitamin D, vitamin E and vitamin PP and in particular to the B vitamins of vitamin B5, vitamin B6 and vitamin B8.

Among the carotenoids, beta-carotene, lycopene, lutein, zeaxanthin, and astaxanthin are preferred.

Particularly useful minerals and trace elements are zinc, calcium, magnesium, copper, iron, iodine, manganese, selenium and chromium (III).

Among the polyphenols, those from grapes, tea, olives, cocoa, coffee, apples, blueberries, elderberries, strawberries, cranberries and onions may be specifically selected.

Preferably, among the phytoestrogens, the isoflavones are chosen in free form or in glycosylated form, such as genistein, daidzein flavone or lignan, in particular those chosen from flax and from schizandra chinensis.

Preferably, among amino acids suitable for use in the present invention, taurine, threonine, cysteine, tryptophan or methionine, or peptides and proteins including the above amino acids may be selected.

Preferably, among the lipids suitable for use in the present invention, the lipids belonging to the family of oils containing: monounsaturated and polyunsaturated fatty acids, such as octadecenoic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, stearidonic acid; long chain fish omega-3 fatty acids, such as EPA and DHA; conjugated fatty acids obtained from plants or animals, such as CLA (conjugated linoleic acid).

Thus, the composition for oral administration may further comprise at least one nutritional active selected from the group consisting of lycopene, vitamin C, vitamin E and polyphenols.

The oral compositions of the present invention may also include other nutritionally active agents selected from the group consisting of:

anti-aging nutritional actives, such as food antioxidants, nutrients with free radical scavenging properties and cofactors for the endogenous enzymes of antioxidants, vitamin a, vitamin C and vitamin E, carotenoids, lutein, isoflavones, some minerals (such as zinc, copper, magnesium or selenium), lipoic acid, coenzyme Q10, superoxide dismutase (SOD) or taurine. Among the anti-ageing active agents that may be mentioned in particular are the unsaponifiable fraction extracted from the fat of the plant source aloe, native or hydrolysed marine collagen and vegetable or marine oils rich in omega-3 and omega-6 fatty acids (containing gamma-linolenic acid),

photoprotective nutritional active agents, such as antioxidants and radical scavengers: vitamin A, vitamin C and vitamin E, carotenoids, lutein, some minerals (e.g., zinc, copper, magnesium or selenium), coenzyme Q10 and superoxide dismutase (SOD),

nutritional ingredients with moisturizing or immunomodulating properties, such as extracts of echeveria glauca, vegetable oils rich in omega-3 fatty acids and omega-6 fatty acids (comprising gamma-linolenic acid) or marine petroleum.

According to another embodiment, the probiotic microorganisms suitable for use in the present invention may advantageously be used orally in combination with a scavenger, for example an extract specifically selected from birch or black radish.

According to another preferred embodiment, the probiotic microorganisms suitable for use in the present invention may be used parenterally, in particular subcutaneously or intradermally, in combination with at least one bulking agent or agent for stimulating the proliferation of fibroblasts or keratinocytes or an agent for stimulating the synthesis of dermal macromolecules.

Advantageously, the probiotic microorganisms suitable for use in the present invention may be used in parenteral combination with an agent selected from the group consisting of: an extract of centella asiatica; asiaticoside and its derivatives; synthesizing a peptide; peptides extracted from plants; plant hormones such as gibberellin and cytokinin; an extract of saccharomyces cerevisiae; an extract of algae macroalgae; retinoids and derivatives thereof; oligopeptides and lipopeptides; a lipoamino acid; malt extract; extracts of blueberry or rosemary; lycopene; isoflavone, isoflavone derivative or plant extract containing isoflavone, red clover, linseed, kudzu root (kakkon) or sage extract; peptide extracts of seeds of leguminous plants (peas); heparin; a pseudodipeptide; lupin extract; extract from beech-the bud (bud) of european beech; extracts of zooplankton Salina (Salina); phloroglucinol; an extract of walnut oil cake; an extract of potato; hyaluronic acid, especially hyaluronic acid having a weight average molecular weight ranging from 50,000 to 3,000,000 daltons.

According to one embodiment, the present invention relates to a cosmetic method for preventing and/or treating impaired radiance of the skin complexion in a subject in need thereof, said method comprising at least one step of administering at least one probiotic microorganism, and in particular lactobacillus, to said subject.

The method according to the invention may comprise the steps consisting in: a reduction or even disappearance of the radiance damage of the skin tone is observed or alternatively an improvement of the radiance of the skin tone is observed.

The method according to the invention can be carried out locally, in particular by applying a topical cosmetic and/or dermatological composition as defined above.

Advantageously, the method of the invention comprising topical application may comprise applying a composition comprising at least one probiotic microorganism according to the invention to the skin, for example in the form of a mask.

Such administration can be carried out according to the usual techniques for using these compositions. For example, it may consist in applying a cream, gel, serum or lotion to the skin or mucous membranes.

For example, topical cosmetic methods according to the present invention may be performed daily, e.g., at a rate of once daily or twice daily (e.g., once in the morning and once in the evening).

The topical cosmetic method according to the invention can be carried out over a period of one week to several weeks, or even several months, and this period can be repeated for several months or even years after the untreated period.

For example, topical administration of probiotic microorganisms according to the invention may be repeated, e.g. 2 to 3 or more times per day, typically over an extended period of at least 4 weeks, or even 4 to 15 weeks, where appropriate, with one or more periods of inactivity.

The cosmetic method according to the invention may comprise oral administration, in particular by administration of a food composition as defined above.

An effective amount of the microorganism may be administered in a single dose per day or in divided doses, for example, two to three times per day.

The oral cosmetic method may be carried out over a period of one week to several weeks, or even several months, and furthermore, this period may be repeated for several months or even years after the untreated period.

For example, oral administration of the probiotic microorganisms according to the invention may be carried out at a rate of, for example, 3 or more times per day over an extended period of time, typically at least 4 weeks, or even 4 to 15 weeks, optionally including one or more periods of inactivity or repeated after periods of inactivity.

Drawings

FIG. 1: the change in facial skin complexion over time at D1, D29, and D57 is shown. The upper panel shows the ST11 group and the lower panel shows the placebo group. The results showed a clear improvement in skin complexion for the individuals of the ST11 group (dark and medium grey bars indicate grade 0 and 1, measured on grade 4). Results are expressed as mean ± confidence interval.

FIG. 2: the change in facial skin defects over time at D1, D29, and D57 is shown. The upper panel shows the ST11 group and the lower panel shows the placebo group. The results show that facial skin imperfections are very significantly reduced for individuals in the ST11 group (dark and medium gray bars indicate a grade 0 and 1, as measured on a 3 scale). Results are expressed as mean ± confidence interval.

Detailed Description

In this description and in the examples that follow, percentages are by weight and ranges of values expressed as "between … and …" include the stated lower and upper limits unless otherwise indicated.

The ingredients are mixed together in sequence and under conditions readily determinable by one skilled in the art prior to formation.

The amounts and characteristics of the ingredients used in the compositions of the present invention are adjusted by those skilled in the art so as not to substantially affect the desired properties of the compositions of the present invention.

The following examples are presented as non-limiting illustrations of the invention.

Examples

Example 1

Effect of food supplement comprising Lactobacillus paracasei ST11 on the radiance of skin complexion

Materials and methods

The effect of the food supplement comprising lactobacillus paracasei ST11 on the radiance of the skin complexion was determined by performing a double-blind random controlled comparative single-center study (double-blind randomised controlled comparative single-center study) on two parallel groups of 33 individuals, namely the food supplement (ST 11 group) and the placebo (placebo group).

Skin tone shine measurements were performed by the evaluating dermatologist with the aid of clinical evaluation.

The individuals selected for this study were healthy males over the age of 60, at the start of the study (D0)In principle they are low consumers of fermented products (less than 125 g/day) with a score of 4 or 5.

During the study, volunteers agreed not to consume any fermented product containing live bacteria (yogurt, cottage cheese, fermented milk, cheese without pasteurization, etc.).

The food supplement is prepared in the form of a powder comprising 10⁹Total dose of cfu of live lactobacillus paracasei NCC 2461 (ST 11) and maltodextrin. The powder is to be dispersed or dissolved in a drinkable liquid, preferably water.

The placebo was formulated in the form of a powder, which included only maltodextrin. The powder is to be dispersed or dissolved in a drinkable liquid, preferably water.

The treatment was administered once a day for 61 days. Measurements were made at D-42 (pre-incorporation), D0, D1, D2, D3, D4, D5, D29, D30, D31, D32, D33, D57, D58, D59, D60 and D61.

The clinical score of the complexion of the face was visually determined by the dermatologist making the investigation at each visit according to the range from 0 to 4 (0 = very shiny; 1= shiny; 2= neither dull nor glossy; 3= dull; 4= very dull).

The clinical score of facial defects (spots, skin disease, skin discoloration, age spots and blackheads) was determined visually by the examining dermatologist at each visit according to a range from 0 to 4 (0 = no: no defects; 1= slightly: few defects (1 to 5); 2= medium: 5 defects to 12 defects; 3= severe: more than 12 and less than 25 defects; 4= extreme: very large number of defects).

Results

Facial skin complexion(FIG. 1)

At D1, the facial skin complexion was similar for both groups (ST 11 and placebo) (p = 0.4412).

On the other hand, over time, the facial skin complexion became significantly brighter and glossier in the ST11 group than in the placebo group. The variation in skin tone radiance between D1 and D57 for both groups was statistically significantly favorable to support the ST11 group (p = 0.0408).

At the end of supplementation, a 54% increase in the brightness of the skin tone was observed for the individuals treated with the food supplement according to the invention, while only a 22% increase was observed for the placebo group.

TABLE 1

Test for intra-and inter-group comparison of changes in facial skin complexion relative to D1 at all times (p-value).

Facial skin defects(FIG. 2)

Skin defects evaluated were in particular spots, skin diseases, skin discoloration, age spots and blackheads.

The two groups ST11 and placebo showed similarities at D1 (p = 0.5901).

On the other hand, facial skin defects were significantly reduced between D1 and D57 for only ST11 group. The variation in facial skin defects between D1 and D57 was statistically significantly favorable to support the ST11 group (p = 0.0175).

At the end of supplementation, a 22% reduction in facial skin defects was observed for the individuals treated with the food supplement according to the invention, whereas a 10% reduction was observed for the placebo group.

TABLE 2

Test for intra-and inter-group comparison of the variation of facial defects with respect to D1 at all times (p-value).

Conclusion

The results obtained in the clinical study detailed above show that, according to clinical evaluation, 10 is used⁹The oral administration of a food supplement comprising lactobacillus paracasei (ST 11) at a dose of cfu/day for two months makes it possible to obtain:

significantly more radiant complexion (p =0.0408 for overall change in complexion between D1 and D57 for ST11 group and placebo group); and

facial defects decreased over time only for ST11 group (p < 0.0001). If this change is studied between D1 and D57 for both treatment groups (p = 0.0175), this difference is statistically significant in support of the ST11 group.

Example 2

Topical compositions according to the invention

Example 2A

Face lotion

Example 2B

Facial care gel

Example 2C

Face care lotion

Example 2D

Face care cream

Example 2E

Facial care gel

Example 3

Oral composition

Example 3A

Powder in stick form

One stick may be applied per day.

Example 3B

Capsule

One to three of these glutinous rice capsules may be applied per day.

Example 3C

Sugar-coated tablet

Sugar-coated tablets of this type may be administered from 1 to 3 times per day.

Example 3D

Sugar-coated tablet

Sugar-coated tablets of this type may be administered from 1 to 3 times per day.

Claims (14)

1. Cosmetic use of at least one probiotic microorganism, in particular of the genus lactobacillus, as an active agent for treating and/or preventing the impaired radiance of the complexion of the skin.

2. Use according to the preceding claim, for preventing and/or treating loss of radiance of the complexion of the skin.

3. Use according to claim 1 or 2, for imparting a shiny complexion to the skin.

4. Use according to any one of the preceding claims, for preventing and/or treating chaotic, dull and/or uneven skin complexion.

5. Use according to any one of the preceding claims, for preventing and/or treating skin defects, in particular selected from spots, skin diseases, skin discolouration, age spots, blackheads and/or chloasma.

6. Use according to any one of the preceding claims, wherein the probiotic micro-organisms may be administered orally, topically or parenterally, and in particular orally.

7. Use according to any one of the preceding claims, wherein the probiotic micro-organisms are used in live, semi-live, inactivated or dead form.

8. Use according to any one of the preceding claims, wherein the probiotic micro-organisms are used in the form of a lysate.

9. Use according to any one of the preceding claims, wherein the probiotic micro-organisms are selected from the group consisting of Lactobacillus, Bifidobacterium, coccus, yeast, sporophytes and mixtures thereof.

10. Use according to any one of the preceding claims, wherein the probiotic micro-organism is Lactobacillus paracasei, and in particular Lactobacillus paracasei CNCMI-2116 (ST 11).

11. Use according to any one of the preceding claims, in which the probiotic microorganism is used in the composition in a proportion of from 0.0001% to 30%, in particular in a proportion of from 0.001% to 20%, more particularly from 0.01% to 15%, in particular from 0.1% to 10% and especially from 1% to 5%, in percentages by weight relative to the total weight of the composition containing it.

12. Use according to any one of claims 1 to 10, wherein the probiotic micro-organisms are used in live form by means of the oral route in the following proportions: 10 viable micro-organisms per gram of the composition comprising said probiotic micro-organisms³cfug to 10¹⁵cfu/g, in particular from 10⁵cfu/g to 10¹⁵cfu/g and more particularly from 10⁷cfu/g to 10¹²cfu/g。

13. Use according to any one of the preceding claims, wherein the probiotic micro-organisms are used in combination with a further active agent.

14. A cosmetic method for preventing and/or treating impaired radiance of the complexion of the skin, said method comprising the administration of at least one probiotic microorganism, in particular of the genus lactobacillus, as defined in any one of claims 6 to 12.